Back to Research Hub
TG Therapeutics, Inc.
TGTX
$43.37+2.42 (+5.91%)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
StreetsValue research for TG Therapeutics, Inc. (TGTX)
Members get the full report for TG Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.